Abstract 14035: High Levels of Antibodies Against Phosphorylcholine and Modified LdL in Combination Confers 8-9 Times Increased Protection Against Atherosclerosis Increase Among Patients With Hypertension: Possible Implications for Immune Therapy
Objective: To determine combinations of antibodies of IgM isotype against phosphorylcholine (anti-PC) and modified forms of low density lipoprotein (malondialdehyde modified (anti-MDALDL) or oxidized LDL (anti-OxLDL) for development of atherosclerosis.
Methods 226 individuals with established hypertension (diastolic pressure >95 mmHg) were from European Lacidipine Study on Atherosclerosis. Antibodies were tested by ELISA. High-sensitivity C-reactive protein was measured by nephelometry. As a surrogate measure of atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in the far walls of common carotids and bifurcations was determined by ultrasonography at the time of enrolment, and 4 years following enrolment.
Results Increases in IMT at follow-up were 8-9 times less common in subjects which at the time of enrolment had high IgM anti-PC in combination with high anti-MDALDL or anti-OxLDL 75th and anti-PC 90th percentile (odds ratios: 0.14; CI: 0.038-0.51; and 0.12; CI: 0.033-0.42 respectively; p<0.005). CRP was not associated with IMT-changes or with anti-PC levels. The relationship between combinations of antibodies and changes in IMT was independent of age, treatment with atenolol or lacidipine, smoking and lipids. Women had higher levels of antibodies tested (p<0.05).
Conclusions: A combination of high levels of anti-PC and anti-MDALDL or anti-OxLDL gave a strikingly high protection (8-9 times less risk) against atherosclerosis development. The possibility that raising the antibodies in combination through immunization could be developed into a novel therapy deserves further attention. Larger studies are needed to determine if such combinations could improve risk evaluation.
- © 2011 by American Heart Association, Inc.